Sign In

Catherine Priestley

Head of BioPharmaceuticals R&D Communications, Global Corporate Affairs at AstraZeneca, communicating how we’re unlocking the power of what science can do to deliver life-changing medicines to patients.

Catherine Priestley is a seasoned corporate affairs professional currently serving as the Head of Global Corporate Affairs for Cardiovascular, Renal, and Metabolism (CVRM) at AstraZeneca, a position she has held since November 2022. In this role, she is part of AstraZeneca’s Global Corporate Affairs Leadership Team, focusing on public relations, communications, policy, and patient advocacy to enhance treatment outcomes for complex diseases.12

Professional Background

Priestley has a long tenure at AstraZeneca, having joined the company in 2003. Her career progression includes several key roles:

  • Head of BioPharmaceuticals R&D and cross-R&D Communications (May 2019 - Present): She led communications for the BioPharmaceuticals R&D organization, aligning efforts with Oncology and Rare Disease R&D.1
  • Director of IMED Communications (September 2018 - November 2022): In this capacity, she managed communications for the IMED Biotech Unit, emphasizing early scientific innovations across various therapy areas.1
  • Science Communications Associate Director (November 2013 - April 2016): Here, she developed scientific content and led events to boost the visibility of the IMED portfolio.1

Education

Catherine holds a BSc with First Class Honours in Medical Science from Birmingham University (1996-2000) and a PhD in Molecular and Genetic Toxicology from Imperial College London (2000-2003).1

Contributions and Vision

Priestley is dedicated to leveraging scientific advancements to deliver life-changing medicines to patients. Her work aims to amplify AstraZeneca's pipeline and celebrate scientific progress both internally and externally.12 She actively engages with the scientific community and participates in various initiatives to promote health outcomes through effective communication strategies.3

Overall, Catherine Priestley exemplifies leadership in corporate affairs within the pharmaceutical industry, focusing on impactful communication strategies that align with AstraZeneca's mission to improve patient lives.

Highlights

Aug 28 · linkedin

I'm very much looking forward to the upcoming European Society of Cardiology (ESC) Congress 2024 in London! AstraZeneca we are committed to advancing medical science and improving patient outcomes. If you're attending, let's connect, collaborate, and continue to push the boundaries of what's possible in cardiovascular health.

May 21 · linkedin

I’m incredibly proud to be part of the AstraZeneca team today.

We’ve unveiled our bold ambition to deliver $80bn in annual revenue by 2030 and sustained growth post 2030. We’ll achieve this by continued growth of our existing portfolio, launching 20 new medicines before the end of the decade and advancing transformative new technologies and platforms that will shape the future of medicine. Importantly, we’ll continue to decouple carbon emissions from revenue growth.

This ambition is a testament to our commitment to pushing the boundaries of science to deliver life-changing medicines. I can’t wait to play my part in making it a reality! #AZN #WhatScienceCanDo

I’m incredibly proud to be part of the AstraZeneca team today. 

We’ve unveiled our bold ambition to

Related Questions

What are Catherine Priestley's main responsibilities at AstraZeneca?
How has Catherine Priestley contributed to AstraZeneca's scientific advancements?
What is Catherine Priestley's educational background?
What therapy areas does Catherine Priestley focus on at AstraZeneca?
How long has Catherine Priestley been with AstraZeneca?
Catherine Priestley
Catherine Priestley, photo 1
Catherine Priestley, photo 2
Add to my network

Location

Cambridge, England, United Kingdom